Compare Stocks: PRAX, BIIB, ALNY, and ROIV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$216.98 -1.0%	$278.55	$197.81 ▼ $495.55	$29.33B	0.3	2.27 million shs	1.40 million shs
BIIB Biogen	$207.13 -0.4%	$202.63	$127.71 ▼ $219.72	$30.72B	0.17	1.35 million shs	706,405 shs
PRAX Praxis Precision Medicines	$366.96 +1.7%	$304.62	$37.19 ▼ $382.54	$10.07B	2.78	383,296 shs	605,048 shs
ROIV Roivant Sciences	$35.78 -1.5%	$33.26	$10.90 ▼ $37.00	$26.14B	1.12	4.89 million shs	7.94 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+6.66%	-26.63%	-23.04%	-50.06%
BIIB Biogen	0.00%	+2.46%	+4.41%	+5.05%	+59.13%
PRAX Praxis Precision Medicines	0.00%	+17.19%	+11.01%	+8.72%	+685.29%
ROIV Roivant Sciences	0.00%	+7.17%	+1.03%	+25.48%	+216.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$216.98 -1.0%	$278.55	$197.81 ▼ $495.55	$29.33B	0.3	2.27 million shs	1.40 million shs
BIIB Biogen	$207.13 -0.4%	$202.63	$127.71 ▼ $219.72	$30.72B	0.17	1.35 million shs	706,405 shs
PRAX Praxis Precision Medicines	$366.96 +1.7%	$304.62	$37.19 ▼ $382.54	$10.07B	2.78	383,296 shs	605,048 shs
ROIV Roivant Sciences	$35.78 -1.5%	$33.26	$10.90 ▼ $37.00	$26.14B	1.12	4.89 million shs	7.94 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+6.66%	-26.63%	-23.04%	-50.06%
BIIB Biogen	0.00%	+2.46%	+4.41%	+5.05%	+59.13%
PRAX Praxis Precision Medicines	0.00%	+17.19%	+11.01%	+8.72%	+685.29%
ROIV Roivant Sciences	0.00%	+7.17%	+1.03%	+25.48%	+216.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.92	Moderate Buy	$396.72	82.84% Upside
BIIB Biogen	2.56	Moderate Buy	$224.61	8.44% Upside
PRAX Praxis Precision Medicines	3.00	Buy	$573.05	56.16% Upside
ROIV Roivant Sciences	2.83	Moderate Buy	$35.14	-1.80% Downside

Current Analyst Ratings Breakdown

Latest PRAX, BIIB, ALNY, and ROIV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	ROIV Roivant Sciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $46.00
8/7/2026	PRAX Praxis Precision Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$449.00 ➝ $462.00
8/7/2026	PRAX Praxis Precision Medicines	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$514.00
8/7/2026	PRAX Praxis Precision Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Positive	$323.00 ➝ $362.00
8/7/2026	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $41.00
8/7/2026	ROIV Roivant Sciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$36.00 ➝ $42.00
8/6/2026	ROIV Roivant Sciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$575.00 ➝ $582.00
8/4/2026	ALNY Alnylam Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$410.00 ➝ $315.00
8/4/2026	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$221.00 ➝ $241.00
8/3/2026	BIIB Biogen	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$200.00 ➝ $215.00

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$4.80B	6.04	$2.77 per share	78.39	$5.97 per share	36.35
BIIB Biogen	$10.03B	3.05	$22.54 per share	9.19	$124.45 per share	1.66
PRAX Praxis Precision Medicines	$8.55M	1,198.31	N/A	N/A	$34.85 per share	10.53
ROIV Roivant Sciences	$8.26M	3,115.68	N/A	N/A	$7.35 per share	4.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	40.33	22.48	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	36.66	12.64	6.42	8.32%	11.18%	6.88%	10/29/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	N/A
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	N/A

Latest PRAX, BIIB, ALNY, and ROIV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
BIIB Biogen	0.39	1.87	1.26
PRAX Praxis Precision Medicines	N/A	15.73	15.73
ROIV Roivant Sciences	N/A	16.72	16.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
PRAX Praxis Precision Medicines	67.84%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
PRAX Praxis Precision Medicines	3.00%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable
ROIV Roivant Sciences	860	719.27 million	655.97 million	Optionable

PRAX, BIIB, ALNY, and ROIV Headlines

Recent News About These Companies

Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $42.00

August 10 at 1:48 AM | americanbankingnews.com

Bank of America Corp DE Has $87.64 Million Stock Position in Roivant Sciences Ltd. $ROIV

August 9 at 3:43 AM | marketbeat.com

Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon

August 8 at 9:00 AM | seekingalpha.com

Sei Investments Co. Acquires 33,508 Shares of Roivant Sciences Ltd. $ROIV

August 8 at 4:39 AM | marketbeat.com

Guggenheim Issues Positive Forecast for Roivant Sciences (NASDAQ:ROIV) Stock Price

August 7 at 1:23 PM | marketbeat.com

Roivant Sciences Q1 Earnings Call Highlights

August 7 at 7:02 AM | marketbeat.com

Assenagon Asset Management S.A. Acquires 1,286,464 Shares of Roivant Sciences Ltd. $ROIV

August 7 at 3:59 AM | marketbeat.com

Roivant outlines brepocitinib DM launch by end of September and targets cutaneous sarcoidosis Phase III data in 2028

August 6, 2026 | seekingalpha.com

Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Roivant Sciences Ltd. 2026 Q1 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

August 6, 2026 | markets.businessinsider.com

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

August 6, 2026 | globenewswire.com

Ausblick: Roivant Sciences stellt Ergebnisse des abgelaufenen Quartals vor

August 5, 2026 | finanzen.netF

Edgestream Partners L.P. Takes Position in Roivant Sciences Ltd. $ROIV

August 4, 2026 | marketbeat.com

Roivant Sciences Ltd. $ROIV Shares Purchased by California State Teachers Retirement System

August 4, 2026 | marketbeat.com

Arrowstreet Capital Limited Partnership Grows Position in Roivant Sciences Ltd. $ROIV

August 4, 2026 | marketbeat.com

Hsbc Holdings PLC Sells 31,577 Shares of Roivant Sciences Ltd. $ROIV

August 3, 2026 | marketbeat.com

Amundi Has $41.02 Million Stake in Roivant Sciences Ltd. $ROIV

August 3, 2026 | marketbeat.com

Seven Fleet Capital Management LP Purchases New Shares in Roivant Sciences Ltd. $ROIV

August 2, 2026 | marketbeat.com

Roivant Sciences Ltd. $ROIV Position Raised by Perceptive Advisors LLC

August 2, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PRAX, BIIB, ALNY, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$216.98 -2.22 (-1.01%)

As of 04:00 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$207.13 -0.81 (-0.39%)

As of 04:00 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Praxis Precision Medicines NASDAQ:PRAX

$366.96 +6.20 (+1.72%)

As of 04:00 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$35.78 -0.56 (-1.54%)

As of 04:00 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRAX, BIIB, ALNY, and ROIV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRAX, BIIB, ALNY, and ROIV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRAX, BIIB, ALNY, and ROIV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PRAX, BIIB, ALNY, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Praxis Precision Medicines NASDAQ:PRAX

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRAX, BIIB, ALNY, and ROIV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRAX, BIIB, ALNY, and ROIV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRAX, BIIB, ALNY, and ROIV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PRAX, BIIB, ALNY, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Praxis Precision Medicines NASDAQ:PRAX

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools